Compare SCYX & ACCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | ACCL |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 36.3M |
| IPO Year | 2014 | 2024 |
| Metric | SCYX | ACCL |
|---|---|---|
| Price | $3.79 | $2.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $36.33 | N/A |
| AVG Volume (30 Days) | ★ 284.7K | 5.6K |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $977.86 | N/A |
| P/E Ratio | ★ N/A | $17.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $1.23 |
| 52 Week High | $6.09 | $5.00 |
| Indicator | SCYX | ACCL |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 45.52 |
| Support Level | $3.53 | $2.41 |
| Resistance Level | $4.30 | $3.07 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 23.92 | 54.43 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.